Activated CD4+ T cells preferentially take up lipid microspheres, but resting cells do not.
Lipid microspheres (LM) used as drug carriers increase the effectiveness and reduce the toxicity of incorporated drugs. The present study is designed to determine whether or not activated T lymphocytes, which were the cells chosen first from the 'inflammatory cells', can take up LM in vitro. LM were labelled with a fluorescent probe, DiI (DiI-LM), to examine the kinetics. Flow cytometric analysis demonstrated that in freshly isolated peripheral blood mononuclear cells (PBMC), monocytes principally took up DiI-LM, while lymphocytes and granulocytes did not. When PBMC were stimulated with immobilized anti-CD3 MoAb and IL-2, cells expressing CD3, CD4, CD8 and CD16 incorporated DiI-LM. Purified CD4+ T cells, obtained by positive panning selection, were stimulated with this system. They were CD25, CD71, LFA-1-positive, and also showed an ability to take up DiI-LM, which resting cells did not. The findings were confirmed by flow cytometry and quantitative analysis of DiI. Confocal micrographs showed fluorescent granules from the probe in the cytoplasm of stimulated CD4+ T cells after incubation with DiI-LM. These results suggest that immunomodulatory agents incorporated into LM might selectively regulate the function of CD4+ or CD8+ T cells when these are activated.
Suzuki
K
K
National Defence Medical College, Saitama, Japan.
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D002478:Cells, Cultured; D004337:Drug Carriers / Q000493:pharmacokinetics*; D005217:Fat Emulsions, Intravenous / Q000493:pharmacokinetics; D005434:Flow Cytometry; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology; D008055:Lipids / Q000493:pharmacokinetics*; D008213:Lymphocyte Activation / Q000502:physiology*; D008863:Microspheres; D016853:Muromonab-CD3 / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology
D004337:Drug Carriers; D005217:Fat Emulsions, Intravenous; D007376:Interleukin-2; D008055:Lipids; D016853:Muromonab-CD3; D011994:Recombinant Proteins